Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling.

PURPOSE Generation of a reactive stroma environment occurs in many human cancers and is likely to promote tumorigenesis. However, reactive stroma in human prostate cancer has not been defined. We examined stromal cell phenotype and expression of extracellular matrix components in an effort to define the reactive stroma environment and to determine its ontogeny during prostate cancer progression. EXPERIMENTAL DESIGN Normal prostate, prostatic intraepithelial neoplasia (PIN), and prostate cancer were examined by immunohistochemistry. Tissue samples included radical prostatectomy specimens, frozen biopsy specimens, and a prostate cancer tissue microarray. A human prostate stromal cell line was used to determine whether transforming growth factor beta1 (TGF-beta1) regulates reactive stroma. RESULTS Compared with normal prostate tissue, reactive stroma in Gleason 3 prostate cancer showed increased vimentin staining and decreased calponin staining (P < 0.001). Double-label immunohistochemistry revealed that reactive stromal cells were vimentin and smooth muscle alpha-actin positive, indicating the myofibroblast phenotype. In addition, reactive stroma cells exhibited elevated collagen I synthesis and expression of tenascin and fibroblast activation protein. Increased vimentin expression and collagen I synthesis were first observed in activated periacinar fibroblasts adjacent to PIN. Similar to previous observations in prostate cancer, TGF-beta1-staining intensity was elevated in PIN. In vitro, TGF-beta1 stimulated human prostatic fibroblasts to switch to the myofibroblast phenotype and to express tenascin. CONCLUSIONS The stromal microenvironment in human prostate cancer is altered compared with normal stroma and exhibits features of a wound repair stroma. Reactive stroma is composed of myofibroblasts and fibroblasts stimulated to express extracellular matrix components. Reactive stroma appears to be initiated during PIN and evolve with cancer progression to effectively displace the normal fibromuscular stroma. These studies and others suggest that TGF-beta1 is a candidate regulator of reactive stroma during prostate cancer progression.

[1]  Gary R. Grotendorst,et al.  Expression of connective tissue growth factor mRNA in the fibrous stroma of mammary tumors. , 1997, The international journal of biochemistry & cell biology.

[2]  R. Dahiya,et al.  Normal Development and Carcinogenesis of the Prostate , 1996, Annals of the New York Academy of Sciences.

[3]  G. Ayala,et al.  Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. , 2002, Cancer research.

[4]  J. Mohler,et al.  In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer , 1997, Clinical & Experimental Metastasis.

[5]  T. Wheeler,et al.  Fresh tissue harvest for research from prostatectomy specimens , 1994, The Prostate.

[6]  M. Bissell,et al.  The tumor-promoting effect of wounding: a possible role for TGF-beta-induced stromal alterations. , 1994, Critical reviews in oncogenesis.

[7]  O. Petersen,et al.  Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[8]  C. Jackson,et al.  Type I collagen fibrils promote rapid vascular tube formation upon contact with the apical side of cultured endothelium. , 1991, Experimental cell research.

[9]  M. Sporn,et al.  Transforming Growth Factor‐β , 1990 .

[10]  Pär Stattin,et al.  Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer , 1998, The Prostate.

[11]  P. Humphrey,et al.  Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma. , 1993, Human pathology.

[12]  H. Dvorak.  Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[13]  P. Scardino,et al.  Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  J. Rhim,et al.  Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  D. Horsfall,et al.  Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. , 2001, Cancer research.

[16]  M. Gerdes,et al.  Localization of Transforming Growth Factor-β1 and Type II Receptor in Developing Normal Human Prostate and Carcinoma Tissues , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[17]  T. Matsumura,et al.  Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. , 1999, Journal of biochemistry.

[18]  Elise C. Kohn,et al.  The microenvironment of the tumour–host interface , 2001, Nature.

[19]  K. Olczyk,et al.  [Wound repair]. , 1998, Postepy higieny i medycyny doswiadczalnej.

[20]  W. Schürch,et al.  Myofibroblastic stromal reaction in carcinoma of the breast: variations of collagenous matrix and structural glycoproteins , 2004, Virchows Archiv A.

[21]  S. Hauptmann,et al.  Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoforms. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[22]  G. Owens,et al.  Regulation of differentiation of vascular smooth muscle cells. , 1995, Physiological reviews.

[23]  M. Sporn,et al.  Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Minna,et al.  Stromal and Epithelial Expression of Tumor Markers Hyaluronic Acid and HYAL1 Hyaluronidase in Prostate Cancer* , 2001, The Journal of Biological Chemistry.

[25]  M. Sporn,et al.  Transforming growth factors. , 1985, Cancer surveys.

[26]  R. Coffey,et al.  Production of transforming growth factors by human colon cancer lines. , 1986, Cancer Research.

[27]  L. Matrisian,et al.  Epithelial-stromal interactions and tumor progression: meeting summary and future directions. , 2001, Cancer research.

[28]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[29]  R. Iozzo.  Tumor stroma as a regulator of neoplastic behavior. Agonistic and antagonistic elements embedded in the same connective tissue. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[30]  F. Algaba,et al.  Morphological identification of the patterns of prostatic intraepithelial neoplasia and their importance , 2000, Journal of clinical pathology.

[31]  T. Sakakura,et al.  Expression of fibronectin and tenascin‐C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas , 1997, International journal of cancer.

[32]  B. Nielsen,et al.  Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[33]  Y. Luqmani,et al.  Transcripts for transforming growth factors in human breast cancer: clinical correlates. , 1990, British Journal of Cancer.

[34]  L. Old,et al.  Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Sporn,et al.  Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta. , 1990, Science.

[36]  P. Hein,et al.  Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium , 2000, Breast Cancer Research.

[37]  Anthony J. Guidi,et al.  Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  K. Miyazono,et al.  Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  J. Park,et al.  Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fibroblasts* , 1999, The Journal of Biological Chemistry.

[40]  G. Ayala,et al.  Reactive stroma in prostate cancer progression. , 2001, The Journal of urology.

[41]  B. Lieubeau,et al.  The role of transforming growth factor beta 1 in the fibroblastic reaction associated with rat colorectal tumor development. , 1994, Cancer research.

[42]  J. Foidart,et al.  The Role of Stroma in Breast Carcinoma Growth In Vivo , 1998, Journal of Mammary Gland Biology and Neoplasia.

[43]  W. Schürch,et al.  Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[44]  Y. Fukabori,et al.  Stimulative Effect of Transforming Growth Factor‐β on Collagen Synthesis by Human Prostatic Stromal Cells In Vitro , 1997, International journal of urology : official journal of the Japanese Urological Association.

[45]  J. Ringel,et al.  Transforming Growth Factor-β1 Induces Desmoplasia in an Experimental Model of Human Pancreatic Carcinoma , 2001 .

[46]  M J Bissell,et al.  The influence of the microenvironment on the malignant phenotype. , 2000, Molecular medicine today.

[47]  A. Desmoulière,et al.  Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts , 1993, The Journal of cell biology.

[48]  M. Bissell,et al.  The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. , 1995, The Journal of clinical investigation.

[49]  Y. Kawarada,et al.  Tenascin is a stromal marker for epithelial malignancy in the mammary gland. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Y. DeClerck.  Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. , 2000, European journal of cancer.

[51]  F. Smedts,et al.  Tenascin-C expression in prostatic intraepithelial neoplasia (PIN): a marker of progression? , 1998, Anticancer research.

[52]  Monique Martin,et al.  Role of stromal myofibroblasts infiltrating colon cancer in tumor invasion. , 1996, Pathology, research and practice.

[53]  J. Healey,et al.  Fibroblast activation protein: Purification, epitope mapping and induction by growth factors , 1994, International journal of cancer.

[54]  M. Kattan,et al.  Transforming growth factor-β1: Comparative immunohistochemical localization in human primary and metastatic prostate cancer , 1995 .

[55]  A. Hochberg,et al.  Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. , 1999, Cancer research.

[56]  M. Grégoire,et al.  The role of fibroblasts in tumor behavior , 1995, Cancer and Metastasis Reviews.

[57]  D. Rowley.  What Might A Stromal Response Mean to Prostate Cancer Progression? , 1998, Cancer and Metastasis Reviews.

[58]  D. Horsfall,et al.  Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  N. Kyprianou,et al.  Down‐regulation of protein and mRNA expression for transforming growth factor‐β (TGF‐β1) type I and type II receptors in human prostate cancer , 1997 .

[60]  M. Steiner,et al.  Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. , 1992, Molecular endocrinology.

[61]  M J Bissell,et al.  Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. , 1996, Physiological reviews.